Consun Pharma Sustainability Profile
Consun Pharma, officially known as China Consun Pharmaceutical Group, is a prominent player in the pharmaceutical industry, headquartered in China (CN). Established in 1995, the company has made significant strides in the development and manufacturing of high-quality pharmaceutical products, primarily focusing on prescription medications and over-the-counter solutions. With a strong operational presence across Asia and expanding into international markets, Consun Pharma is recognised for its commitment to innovation and quality. The company’s core offerings include a diverse range of therapeutic drugs, particularly in the fields of cardiovascular health and anti-infectives, distinguished by their efficacy and safety profiles. Notably, Consun Pharma has achieved several milestones, including certifications from international regulatory bodies, which solidify its market position as a trusted provider in the global pharmaceutical landscape.
DitchCarbon Score
How does Consun Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Consun Pharma's score of 19 is lower than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Consun Pharma's reported carbon emissions
In 2023, Consun Pharma, headquartered in China (CN), reported total carbon emissions of approximately 79,125,220 kg CO2e. This figure includes 54,210,460 kg CO2e from Scope 1 emissions, primarily from stationary combustion, and 24,914,760 kg CO2e from Scope 2 emissions, mainly from purchased electricity. Comparatively, in 2022, the company recorded total emissions of about 72,057,200 kg CO2e, with Scope 1 emissions at 53,214,680 kg CO2e and Scope 2 emissions at 18,842,520 kg CO2e. This indicates a rise in emissions from 2022 to 2023, highlighting the need for enhanced climate action. Despite the increase in emissions, Consun Pharma has not disclosed any specific reduction targets or initiatives as part of their climate commitments. The company does not appear to have cascaded any emissions data from a parent organization, nor have they set Science-Based Targets Initiative (SBTi) targets. Overall, while Consun Pharma's emissions data reflects significant operational impacts, the absence of reduction strategies underscores an opportunity for the company to enhance its climate commitments and align with industry standards for sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Scope 1 | 12,611,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 7,978,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - | - |
How Carbon Intensive is Consun Pharma's Industry?
How Carbon Intensive is Consun Pharma's Location?
Consun Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Consun Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
